Published in Eur J Clin Pharmacol on October 20, 2011
KLF8 and FAK cooperatively enrich the active MMP14 on the cell surface required for the metastatic progression of breast cancer. Oncogene (2013) 0.96
Cytochrome P450 Oxidoreductase Influences CYP2B6 Activity in Cyclophosphamide Bioactivation. PLoS One (2015) 0.78
Taxane Combination Chemotherapy in Breast Cancer: Experience from a Tertiary Cancer Centre in India. Indian J Med Paediatr Oncol (2017) 0.75
Genetic markers in CYP2C19 and CYP2B6 for prediction of cyclophosphamide's 4-hydroxylation, efficacy and side effects in Chinese patients with systemic lupus erythematosus. Br J Clin Pharmacol (2015) 0.75
Effects of cytochrome P450 family 3 subfamily A member 5 gene polymorphisms on daunorubicin metabolism and adverse reactions in patients with acute leukemia. Mol Med Rep (2017) 0.75
Cytochrome P450 2J2, a new key enzyme in cyclophosphamide bioactivation and a potential biomarker for hematological malignancies. Pharmacogenomics J (2015) 0.75
Global trends in breast cancer incidence and mortality 1973-1997. Int J Epidemiol (2005) 3.01
Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation. Pharmacogenomics J (2003) 1.44
Pharmacogenetics of cyclophosphamide in patients with hematological malignancies. Eur J Pharm Sci (2005) 1.30
Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos (1999) 1.30
Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide. Pharmacogenet Genomics (2008) 1.28
Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. Arthritis Rheum (2004) 1.25
Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P450 2C19. Pharmacogenomics J (2005) 1.19
Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. Pharmacogenetics (1997) 1.18
Aldehyde dehydrogenase-mediated cellular relative insensitivity to the oxazaphosphorines. Curr Pharm Des (1999) 1.17
Subunit diversity and tissue distribution of human glutathione S-transferases: interpretations based on electrospray ionization-MS and peptide sequence-specific antisera. Biochem J (1997) 1.11
Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients. Pharmacogenet Genomics (2007) 1.08
Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation. Health Technol Assess (2007) 1.00
Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes. Cancer Res (1997) 0.98
Involvement of human glutathione S-transferase isoenzymes in the conjugation of cyclophosphamide metabolites with glutathione. Cancer Res (1994) 0.95
Glutathione S-transferase overexpression protects against anthracycline-induced H9C2 cell death. Am J Physiol Heart Circ Physiol (2004) 0.93
Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes. Eur J Clin Pharmacol (2003) 0.90
Gene polymorphisms in cyclophosphamide metabolism pathway,treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancer. Clin Cancer Res (2010) 0.89
Cancer chemotherapy and drug metabolism. Drug Metab Dispos (2005) 0.87
Genotype frequencies of selected drug metabolizing enzymes and ABC drug transporters among breast cancer patients on FAC chemotherapy. Basic Clin Pharmacol Toxicol (2010) 0.82
Serious haematological toxicity of cyclophosphamide in relation to CYP2B6, GSTA1 and GSTP1 polymorphisms. Br J Clin Pharmacol (2007) 0.77
Application of liquid chromatography-mass spectrometry to monitoring plasma cyclophosphamide levels in phase I trial cancer patients. Clin Exp Pharmacol Physiol (2004) 0.77
Influence of CYP3A4, CYP3A5, and ABCB1 genotype and expression on budesonide pharmacokinetics: a possible role of intestinal CYP3A4 expression. Clin Pharmacol Ther (2008) 0.76
Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology (2003) 2.97
Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Clin Pharmacol Ther (2002) 2.01
CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects. Clin Pharmacol Ther (2004) 1.99
Clinical pharmacology in research, teaching and health care: Considerations by IUPHAR, the International Union of Basic and Clinical Pharmacology. Basic Clin Pharmacol Toxicol (2010) 1.96
Deposition of Alzheimer's beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics (2002) 1.75
Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther (2002) 1.58
Functional significance of a hereditary adenine insertion variant in the 5'-UTR of the endothelin-1 gene. Pharmacogenetics (2003) 1.51
MDR1-P-Glycoprotein (ABCB1) Mediates Transport of Alzheimer's amyloid-beta peptides--implications for the mechanisms of Abeta clearance at the blood-brain barrier. Brain Pathol (2007) 1.45
Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses? Antimicrob Agents Chemother (2005) 1.42
The role of P-glycoprotein in cerebral amyloid angiopathy; implications for the early pathogenesis of Alzheimer's disease. Curr Alzheimer Res (2004) 1.42
Meta- and pooled analyses of GSTM1, GSTT1, GSTP1, and CYP1A1 genotypes and risk of head and neck cancer. Cancer Epidemiol Biomarkers Prev (2003) 1.40
Pakistan--country profile of cancer and cancer control 1995-2004. J Pak Med Assoc (2006) 1.31
CYP1A1 and GSTM1 genetic polymorphisms and lung cancer risk in Caucasian non-smokers: a pooled analysis. Carcinogenesis (2003) 1.28
The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmacol Ther (2002) 1.23
CYP1A1 and GSTM1 genotypes affect benzo[a]pyrene DNA adducts in smokers' lung: comparison with aromatic/hydrophobic adduct formation. Carcinogenesis (2002) 1.23
Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur J Clin Pharmacol (2003) 1.20
Influence of genetic polymorphisms on intestinal expression and rifampicin-type induction of ABCC2 and on bioavailability of talinolol. Pharmacogenet Genomics (2008) 1.18
Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosis. J Clin Psychiatry (2010) 1.16
Educating European (junior) doctors for safe prescribing. Basic Clin Pharmacol Toxicol (2007) 1.15
Variable expression of MRP2 (ABCC2) in human placenta: influence of gestational age and cellular differentiation. Drug Metab Dispos (2005) 1.14
CYP1A1 T3801 C polymorphism and lung cancer: a pooled analysis of 2451 cases and 3358 controls. Int J Cancer (2003) 1.13
The ATP-binding cassette transporter ABCG2 (BCRP), a marker for side population stem cells, is expressed in human heart. J Histochem Cytochem (2005) 1.10
[Hypoglycemic risk of insulinotropic drugs]. Med Monatsschr Pharm (2009) 1.05
Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans. Clin Pharmacol Ther (2004) 1.05
The challenges of clinical trials in fragile X syndrome. Psychopharmacology (Berl) (2013) 1.05
Pooled analysis of the CYP1A1 exon 7 polymorphism and lung cancer (United States). Cancer Causes Control (2003) 1.04
A LC-MS/MS method to quantify the novel cholesterol lowering drug ezetimibe in human serum, urine and feces in healthy subjects genotyped for SLCO1B1. J Chromatogr B Analyt Technol Biomed Life Sci (2005) 1.04
Epidemiological review of head and neck cancers in Karachi. Asian Pac J Cancer Prev (2006) 1.03
Incidence and current trends of colorectal malignancies in an unscreened, low risk Pakistan population. Asian Pac J Cancer Prev (2011) 1.02
Transient receptor potential channel polymorphisms are associated with the somatosensory function in neuropathic pain patients. PLoS One (2011) 1.02
Non-response to antiepileptic pharmacotherapy is associated with the ABCC2 -24C>T polymorphism in young and adult patients with epilepsy. Pharmacogenet Genomics (2009) 1.02
Down-regulation of ATP-binding cassette C2 protein expression in HepG2 cells after rifampicin treatment is mediated by microRNA-379. Mol Pharmacol (2011) 1.01
MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. Br J Clin Pharmacol (2002) 0.99
Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate-glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans. Clin Pharmacol Ther (2006) 0.99
miRNAs as mediators of drug resistance. Epigenomics (2012) 0.98
Paediatric adverse drug reactions reported in Sweden from 1987 to 2001. Pharmacoepidemiol Drug Saf (2005) 0.96
Cancer of the oral cavity and pharynx in Karachi--identification of potential risk factors. Asian Pac J Cancer Prev (2003) 0.95
Pharmacogenetics of ATP-binding cassette transporters and clinical implications. Methods Mol Biol (2010) 0.95
Patho-epidemiology of Cancer Cervix in Karachi South. Asian Pac J Cancer Prev (2007) 0.95
Metabolic gene polymorphisms and lung cancer risk in non-smokers. An update of the GSEC study. Mutat Res (2005) 0.94
Myeloperoxidase G-463A polymorphism and lung cancer: a HuGE genetic susceptibility to environmental carcinogens pooled analysis. Genet Med (2007) 0.94
Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance. Expert Opin Drug Metab Toxicol (2014) 0.94
High DNA damage by benzo[a]pyrene 7,8-diol-9,10-epoxide in bronchial epithelial cells from patients with lung cancer: comparison with lung parenchyma. Cancer Lett (2004) 0.91
OpenVigil--free eyeballs on AERS pharmacovigilance data. Nat Biotechnol (2012) 0.90
Expression and localization of the multidrug resistance protein 5 (MRP5/ABCC5), a cellular export pump for cyclic nucleotides, in human heart. Am J Pathol (2003) 0.90
MicroRNA profiling in K-562 cells under imatinib treatment: influence of miR-212 and miR-328 on ABCG2 expression. Pharmacogenet Genomics (2012) 0.90
Modulation of multidrug resistance P-glycoprotein 1 (ABCB1) expression in human heart by hereditary polymorphisms. Pharmacogenetics (2004) 0.90
Patho-epidemiology of breast cancer in Karachi '1995-1997'. Asian Pac J Cancer Prev (2007) 0.90
Association of metabolic gene polymorphisms with tobacco consumption in healthy controls. Int J Cancer (2004) 0.89
Which Genetic Determinants Should be Considered for Tacrolimus Dose Optimization in Kidney Transplantation? A Combined Analysis of Genes Affecting the CYP3A Locus. Ther Drug Monit (2015) 0.89
Expression and localization of P-glycoprotein in human heart: effects of cardiomyopathy. J Histochem Cytochem (2002) 0.89
Epigenetic modulation of the drug resistance genes MGMT, ABCB1 and ABCG2 in glioblastoma multiforme. BMC Cancer (2013) 0.89
Impact of myeloperoxidase and NADPH-oxidase polymorphisms in drug-induced agranulocytosis. J Clin Psychopharmacol (2004) 0.87
Incidence, trends and morphology of ovarian cancer in Karachi (1995-2002). Asian Pac J Cancer Prev (2011) 0.87
Increasing incidence of non-Hodgkin's lymphoma in Karachi, 1995-2002. Asian Pac J Cancer Prev (2005) 0.86
Antimicrobial peptides and proteins of the horse--insights into a well-armed organism. Vet Res (2011) 0.86
Decreased levels of dopamine D3 receptor mRNA in schizophrenic and bipolar patients. Neuropsychobiology (2004) 0.85
Cancer profile of Hyderabad, Pakistan 1998-2002. Asian Pac J Cancer Prev (2006) 0.85
Endothelial NO synthase polymorphisms and postural tachycardia syndrome. Hypertension (2005) 0.85
Endothelial nitric oxide synthase Glu(298)-->Asp polymorphism, carotid atherosclerosis and intima-media thickness in a general population sample. Clin Sci (Lond) (2005) 0.84
Epidemiology of soft tissue sarcomas in Karachi South, Pakistan (1995-7). Asian Pac J Cancer Prev (2009) 0.84
Development of mavoglurant and its potential for the treatment of fragile X syndrome. Expert Opin Investig Drugs (2013) 0.83
MicroRNAs and their relevance to ABC transporters. Br J Clin Pharmacol (2014) 0.83
Identification and functional analysis of genetic variants of the human beta-glucuronidase in a German population sample. Pharmacogenet Genomics (2005) 0.83
Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms. Br J Clin Pharmacol (2006) 0.82
Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1). Clin Cancer Res (2013) 0.82
Genotype frequencies of selected drug metabolizing enzymes and ABC drug transporters among breast cancer patients on FAC chemotherapy. Basic Clin Pharmacol Toxicol (2010) 0.82
Pharmacogenetics-based new therapeutic concepts. Drug Metab Rev (2004) 0.81
Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteers. Pharmacogenetics (2004) 0.81
Impact of ABCC2 genotype on antiepileptic drug response in Caucasian patients with childhood epilepsy. Pharmacogenet Genomics (2011) 0.81
Lack of association between arylamine N-acetyltransferase 2 (NAT2) polymorphism and systemic lupus erythematosus. Pharmacogenetics (2002) 0.81
Differential expression and functionality of TRPA1 protein genetic variants in conditions of thermal stimulation. J Biol Chem (2012) 0.81
Decreased sigmoidal ABCB1 (P-glycoprotein) expression in ulcerative colitis is associated with disease activity. Pharmacogenomics (2009) 0.81
Analysis of alternative promoter usage in expression of HSD11B1 including the development of a transcript-specific quantitative real-time PCR method. Chem Biol Interact (2011) 0.81
Association of ATP-binding cassette transporter variants with the risk of Alzheimer's disease. Pharmacogenomics (2013) 0.80
Clinical implementation of pharmacogenetics: a nonrepresentative explorative survey to participants of WorldPharma 2010. Pharmacogenomics (2011) 0.80
'Comparison of extremes' approach provides evidence against the modifying role of NAT2 polymorphism in lung cancer susceptibility. Cancer Lett (2005) 0.80
Patho-epidemiology of cancer corpus uteri in Karachi South '1995-1997'. Asian Pac J Cancer Prev (2008) 0.80
Endothelial nitric oxide synthase Glu298Asp gene polymorphism, blood pressure and hypertension in a general population sample. J Hypertens (2005) 0.80